Redcare Pharmacy (XTRA:RDC) Shares Just Moved, So What Is Behind It?
Redcare Pharmacy earnings update and guidance confirmation
Redcare Pharmacy (XTRA:RDC) reported updated figures after confirming its 2026 revenue guidance for 16% to 18% growth and releasing nine-month results that show higher sales and a smaller net loss.
Recent trading reflects that optimism. Redcare Pharmacy's share price is up 19.17% over the past 90 days and 11.51% year to date, while the 1-year total shareholder return of 13.48% contrasts with a 36.15% decline over three years and a 51.06% drop over five years. This indicates improving momentum after a difficult longer stretch.
Scan how Redcare Pharmacy compares with other higher quality, potentially mispriced retailers by reviewing the hand picked 199 high quality undervalued stocks.
After a sharp rebound in Redcare Pharmacy shares and fresh confirmation of double digit revenue growth targets, the real tension now is simple: does the potential upside still outweigh the very real risks baked into the price?
Most Popular Narrative: 17% Undervalued
On the analyst consensus Narrative on Simply Wall St, Redcare Pharmacy screens as undervalued, with a fair value of €88.8 against a last close of €73.65, using a 5.48% discount rate and long term earnings and revenue forecasts.
Scaling of logistics investments such as the new Pilsen center and the Sevenum automation project, which target up to 70% lower labor cost per order and capacity increases from 2027, is expected to improve fulfillment efficiency and support adjusted EBITDA margin and net profit.
See why 11 investors see Redcare Pharmacy as 17% undervalued.
Result: Fair Value of €88.8 (UNDERVALUED)
Still, the story can break if German or wider European prescription rules turn less favorable, or if non prescription competitors force higher marketing spend that squeezes margins.
Find out about the key risks to this Redcare Pharmacy narrative.
Another View: What Redcare Pharmacy’s P/S Ratio Signals
The story looks very different when you step away from discounted cash flows and focus on what investors actually pay per euro of sales. Redcare Pharmacy trades on a P/S ratio of 0.5x. That is below peers at 0.6x, yet sits far above its own fair ratio estimate of 0.1x. This is the level the market could move toward if sentiment cools.
This gap suggests the share price already bakes in a lot of optimism relative to that fair ratio, even if it still looks slightly cheaper than similar retailers. For you, the key question is simple: Is that premium to the fair ratio a risk worth taking for a business that is still loss making?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals around Redcare Pharmacy can be confusing, and waiting on perfect clarity often means reacting late instead of early. To weigh the risk and reward trade off for yourself, start with the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Redcare Pharmacy?
You have fresh insight on Redcare Pharmacy right now, so keep that momentum going and line up a few other potential candidates before the market moves.
- Target income first and screen for companies built around reliable cash returns with the 216 dividend fortresses.
- Hunt for quality at a discount and sort through a curated pool of potential bargains using the 567 high quality undiscovered gems.
- Prioritize resilience and filter for businesses with steadier profiles through the 204 resilient stocks with low risk scores.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com